The exclusive distrivution agreement between Gen İlaç ve Sağlık ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and IntraBio Inc. based in the United States of America was signed and entered into force.
According to this agreement, GEN became exclusive distributor of the drug which levacetylleucine active substanced and Agneursa named in Türkiye.
The subjected drug; used in the treatment of Niemann-Pick Type C (NPC) disease, which is a progressive, irreversible genetic lysosomal storage disease that affects the nervous system and some other organs.
After the agreement entered into force necessary process will be followed for addition of the drug to the Abroad Drug List by the Republic of Türkiye Ministry of Health and after the completion of the process supply and sales of the drug within the Named Patient Program (NPP) will be made. This agreement will be effective for 5 years after the first sale of the drug in our country.
